Notice of Appeal


Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

This appeal hearing will hear appeals against the Final Draft Guidance for the above technology by the following organisations:

  • Immunocore

  • Melanoma Focus

  • OcuMel UK

The appeal panel will convene on Friday 20 October at 10.00am via Zoom to hear oral representations from the appellants.